Congenital hyperinsulinism medical therapy

Revision as of 17:58, 20 September 2012 by Kalsang Dolma (talk | contribs) (Created page with "__NOTOC__ {{Congenital hyperinsulinism}} {{CMG}} ==Overview== ==Medical Therapy== Acute hypoglycemia is immediately reversed by raising the blood glucose, but in most forms...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Congenital hyperinsulinism Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital hyperinsulinism from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Congenital hyperinsulinism medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Congenital hyperinsulinism medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congenital hyperinsulinism medical therapy

CDC on Congenital hyperinsulinism medical therapy

Congenital hyperinsulinism medical therapy in the news

Blogs on Congenital hyperinsulinism medical therapy

Directions to Hospitals Treating Congenital hyperinsulinism

Risk calculators and risk factors for Congenital hyperinsulinism medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Medical Therapy

Acute hypoglycemia is immediately reversed by raising the blood glucose, but in most forms of congenital hyperinsulinism hypoglycemia recurs and the therapeutic effort is directed toward preventing falls and maintaining a glucose above 70 mg/dl (3.9 mM). Some of the following measures are often tried:

Each treatment has its limitations and disadvantages or hazards. Many of the treatments do not effectively maintain a satisfactory blood glucose in the more severe cases. Many of the treatments aggravate the poor feeding behavior that often accompanies severe congenital hyperinsulinism. It is hard for parents to continue frequent feedings for many months. Increased calories and corn starch may produce excessive weight gain. Unexpected interruptions of continuous feeding regimens can result in sudden, severe hypoglycemia. Insertion and maintenance of nasogastric tubes is distasteful to parents. Gastrostomy tube insertion requires a minor surgical procedure. Prolonged glucocorticoid use incurs the many unpleasant side effects of Cushing's syndrome. Diazoxide can cause fluid retention requiring concomitant use of a diuretic, and prolonged use causes hypertrichosis. Diazoxide works by opening the KATP channels of the beta cells, and many of the Kir and SUR mutations are unresponsive. Octreotide must be given by injection several times a day or a subcutaneous pump must be inserted every few days. Octreotide can cause abdominal discomfort and responsiveness to octreotide often wanes over time. Glucagon requires continuous intravenous infusion, incurring the infection and blood clot hazards of prolonged central venous lines. Nifedipine is effective only in a minority, and dose is often limited by hypotension.

The relative rarity of this condition and the difficulty of both diagnosis and treatment has resulted in only a few centers around the world developing the expertise to achieve optimal surgical outcomes for these infants: the Children's Hospital of Philadelphia, the Great Ormond Street Hospital for Children in London, as well as centers in Paris and Israel.

References


Template:WikiDoc Sources